Search Within

Ellen M Hollywood

Formats
  1. Meeting Abstract (23)
  2. Journal Article (17)
  3. Book Section (1)
Groups
  1. Advanced Practice Providers (41)
  2. Nursing (41)
  3. Department of Medicine (37)
  4. Gastrointestinal Oncology Service (37)
  5. Solid Tumor Oncology Division (37)
  6. Center for Pancreatic Cancer Research (28)

More Groups

People
  1. Leonard Saltz (27)
  2. Eileen O'Reilly (15)
  3. Marinela Capanu (14)
  4. Ghassan Abou-Alfa (11)
  5. David Kelsen (9)
  6. James Harding (9)

More People

Years
  1. 2019 (1)
  2. 2018 (4)
  3. 2017 (4)
  4. 2015 (3)
  5. 2014 (3)
  6. 2013 (2)

More Years

Publications
  1. Journal of Clinical Oncology (22)
  2. Clinical Cancer Research (3)
  3. Annals of Oncology (2)
  4. Cancer (2)
  5. European Journal of Cancer (2)
  6. Oncology Nursing Forum (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (22)
  2. American Association for Cancer Research (3)
  3. Elsevier Inc. (3)
  4. Oxford University Press (3)
  5. Oncology Nursing Society (ONS) (2)
  6. Springer (2)

More Publishers

Results (41)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: The BOND-2 study
    Journal Article

    Saltz, L. B.; Lenz, H. J.; Kindler, H. L.; Hochster, H. S.; Wadler, S.; Hoff, P. M.; Kemeny, N. E.; Hollywood, E. M.; Gonen, M.; Quinones, M.; more...
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Bevacizumab 5 mg/kg can be infused safely over 10 minutes
    Journal Article

    Reidy, D. L.; Chung, K. Y.; Timoney, J. P.; Park, V. J.; Hollywood, E.; Sklarin, N. T.; Muller, R. J.; Saltz, L. B.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Simplification of bevacizumab (bev) administration: Do we need 90, 60, or even 30 minute infusion times?
    Meeting Abstract

    Saltz, L. B.; Chung, K. Y.; Timoney, J.; Park, V.; Hollywood, E.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Phase I trial of preoperative cetuximab with concurrent continuous infusion 5-fluorouracil and pelvic radiation in patients with local-regionally advanced rectal cancer
    Meeting Abstract

    Chung, K. Y.; Minsky, B.; Schrag, D.; O'reilly, E.; D'adamo, D.; Hollywood, E.; Quinones, M.; Saltz, L.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer
    Meeting Abstract

    Saltz, L. B.; Lenz, H. J.; Hochster, H.; Wadler, S.; Hoff, P.; Kemeny, N.; Hollywood, E.; Gonen, M.; Wetherbee, S.; Chen, H.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • The alphabet soup of colorectal cancer treatment regimens
    Meeting Abstract

    Semple, D.; Hollywood, E.
    Oncology Nursing Forum (2004)

    Fulltext@MSK | Save
  • The collaborative relationship between research and ambulatory care nurses in a GI medical oncology practice
    Meeting Abstract

    Hollywood, E.; Semple, D.
    Oncology Nursing Forum (2004)

    Fulltext@MSK | Save
  • Phase I and pharmacokinetic trial of a novel inhibitor of NAD biosynthesis in patients with solid tumors
    Meeting Abstract

    Holen, K. D.; Bolling, C.; Saltz, L. B.; Graefe, T.; Ty, V.; Sogo, N.; Starkmann, H.; Burk, K. H.; Hollywood, E.; Hanauske, A. R.
    Clinical Cancer Research (2003)

    Fulltext@MSK | Save
  • Clinical issues in the administration of an anti-epidermal growth factor receptor monoclonal antibody, IMC-C225
    Journal Article

    Hollywood, E.
    Seminars in Oncology Nursing (2002)

    Fulltext@MSK | Save
  • A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan
    Journal Article

    Zhu, Y.; Sharma, S.; Saltz, L. B.; Kemeny, N.; Kelsen, D. P.; Ilson, D.; O'reilly, E.; Zaknoen, S.; Baum, C.; Statkevich, P.; more...
    Annals of Oncology (2002)

    Fulltext@MSK | Save